Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Research may lead to new treatments for intestinal disorders

University of Minnesota researchers have found a group of cells in the intestinal system of mice that are proven to turn on T-cells, cells that help fight infection.

24 May 2006

Arthritis drug wins approval for use in children with Crohn's disease

The Food and Drug Administration in the U.S. has given approval for the drug Remicade for use in children with active Crohn's disease(CD), a chronic and debilitating condition.

21 May 2006

Study shows strong association between treatment with TNF-blocking antibodies and development of serious infections

A new meta-analysis of many previous studies of TNF- (tumor necrosis factor) blocking antibodies for treatment of rheumatoid arthritis has confirmed a previously discovered increased risk for serious infection and has found that cancer also is a potential risk associated with the drugs.

17 May 2006

Remicade (infliximab) gains Australian approval for treatment of early rheumatoid arthritis

Schering-Plough Corporation today announced that the Therapeutic Goods Administration of the Department of Health and Ageing in Australia has revised the indication of Remicade (infliximab) to include the treatment of early rheumatoid arthritis (RA) and approved a new indication for psoriatic arthritis (PsA).

23 Mar 2006

Revatio now available in the UK

Patients in the UK suffering from a rare life-threatening heart condition, pulmonary arterial hypertension (PAH), could soon be offered a new treatment.

8 Mar 2006

Extensive study of natalizumab

Scientists have completed an extensive study of more than 3,000 patients who received a promising anti-inflammatory drug, natalizumab, that was linked to three cases of a serious brain infection in large clinical trials halted in early 2005.

7 Mar 2006

Data from Novogen inflammatory bowel disease drug Phase I clinical trial shows promise

A recently completed Phase 1 clinical trial of an investigational drug to treat inflammatory bowel disease has demonstrated rapid absorption indicating potential for development as an oral therapy.

6 Mar 2006

UCB submits application to FDA for new treatment in Crohn's disease

UCB has announced the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for the approval of CIMZIA (certolizumab pegol, CDP870) for the treatment of patients with Crohn's disease.

6 Mar 2006

Is persistent bacterial infection good for your health?

Bacteria are bad. Mothers and doctors, not to mention the cleaning product industry, repeatedly warn of their dangers. But a Stanford University School of Medicine microbiologist is raising the intriguing idea that persistent bacterial and viral infections have benefits.

27 Feb 2006

Viagra could cure Crohn's disease

Crohn's disease is a chronic inflammatory bowel disorder which causes ulcerations in the gut and can make digesting food painful.

27 Feb 2006

Protein levels predict bone marrow transplant survival

Researchers say that protein levels can predict which bone marrow transplant patients are likely develop a deadly complication a week after the procedure and well before any symptoms occur.

19 Feb 2006

Protein level predicts who will develop graft vs. host disease after marrow transplant

Researchers could determine one week after a bone marrow transplant which patients were likely to develop a serious and deadly complication, making them candidates for preventive treatment before any symptoms occur.

17 Feb 2006

Drugs formerly contraindicated for inflammatory bowel disease prove beneficial for pain relief

According to two studies published in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, prescription painkillers are effective in easing the pain of patients with dormant inflammatory bowel disease (IBD) and are not likely to cause symptom flare-ups in IBD patients in remissions

12 Feb 2006

CT enteroclysis should replace conventional enteroclysis in patients with Crohn's disease

The diagnostic value of CT enteroclysis is superior to conventional enteroclysis, previously considered the gold standard, as an imaging method for the evaluation of the small bowel in patients with Crohn's disease, a new study shows.

7 Feb 2006

Eosinophilic esophagitis gene discovery

Researchers at Cincinnati Children's Hospital Medical Center have discovered the first gene associated with eosinophilic esophagitis, one of a number of eosinophil-related diseases in which the body produces abnormally large amounts of white blood cells that can lead to allergy related illnesses.

7 Feb 2006

New biochip predicts evolution of inflammatory bowel disease

The treatment of inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, has very high costs and can include admissions and surgical interventions. Until now, there was no precise tools to predict the evolution and prognosis of these diseases.

26 Jan 2006

Increased attention should be paid to incontinence

It's a topic that is discussed so infrequently - for reasons that are easy to understand - that it may seem it isn't much of a problem. But new research shows that fecal incontinence is prevalent among U.S. women, especially those in older age groups

18 Jan 2006

Protein finding could lead to new topical treatment for inflammatory diseases

A protein that undesirably shields a skin poxvirus from the immune system may become the key ingredient in a new topical treatment for inflammatory diseases, say medical researchers at the University of Illinois at Urbana-Champaign.

11 Jan 2006

Sydney researchers explain how stress makes you sick

Garvan Institute scientists have discovered how a hormone, known as neuropeptide Y (NPY), can prevent our immune system functioning properly, paving the way for two new major opportunities for therapeutic intervention.

10 Jan 2006

Loyola to study for first time IV medication for osteopenia and inflammatory bowel diseases

Researchers at the Osteoporosis and Metabolic Bone Disease Center and the Division of Gastroenterology at Loyola University Health System are studying a once-yearly, 15-minute infusion of an intravenous (IV) medication in patients with osteopenia (low bone mass) and inflammatory bowel diseases (IBD) that, if proven effective, may be considered the standard of treatment.

10 Jan 2006